Drinabant, a highly selective CB1R agonist, presented anti-depression and food-limiting effects in animal models and reached phase IIb clinical trials, but it was shortly withdrawn since it induced symptoms of severe psychiatric disorders in humans [211,214,215]. The gene discussed is CNR1; the disease is major depressive disorder.